Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANRO
stocks logo

ANRO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.440
-15.38%
--
--
-0.575
+2.68%
--
--
-0.610
-6.15%
Estimates Revision
Stock Price
Go Up
up Image
+264.58%
In Past 3 Month
Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 30.71 USD with a low forecast of 15.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 30.71 USD with a low forecast of 15.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.380
sliders
Low
15.00
Averages
30.71
High
50.00
Current: 13.380
sliders
Low
15.00
Averages
30.71
High
50.00
BTIG
Thomas Shrader
initiated
$27
2025-11-17
Reason
BTIG
Thomas Shrader
Price Target
$27
2025-11-17
initiated
Reason
BTIG analyst Thomas Shrader initiated coverage of Alto Neuroscience with a Buy rating and $27 price target. The company is focused on next-generation drugs in psychiatry, including major depressive disorder and treatment-resistant depression, the analyst tells investors in a research note. The firm says each of Alto's programs is supported by "innovative" biomarkers to define subgroups of patients most likely to respond to the specific mechanism of the drug. It sees "several near-term validating" data readouts for the company.
Baird
Outperform
maintain
$16 -> $22
2025-11-13
Reason
Baird
Price Target
$16 -> $22
2025-11-13
maintain
Outperform
Reason
Baird raised the firm's price target on Alto Neuroscience to $22 from $16 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results which suggests clinical progress continues ahead of a catalyst-rich 2026.
Jefferies
Andrew Tsai
Buy
upgrade
$15 -> $25
2025-11-12
Reason
Jefferies
Andrew Tsai
Price Target
$15 -> $25
2025-11-12
upgrade
Buy
Reason
Jefferies analyst Andrew Tsai raised the firm's price target on Alto Neuroscience to $25 from $15 and keeps a Buy rating on the shares. Investor confidence in Alto's precision psychiatry approach could rise in 2026 as ALTO-101 has Phase II data in Q1 2026 for CIAS, ALTO-300 has full Phase IIb data in mid-2026 in MDD depression, ALTO-100 has Phase IIa data in BPD depression in the second half of 2026, and as investors seem most keen on ALTO-207, whose Phase IIb timelines were recently accelerated.
H.C. Wainwright
NULL -> Buy
upgrade
$10 -> $50
2025-10-24
Reason
H.C. Wainwright
Price Target
$10 -> $50
2025-10-24
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Alto Neuroscience to $50 from $10 and keeps a Buy rating on the shares. The firm incorporated the potential value from ALTO-207 in treatment-resistant depression into the company's model. The target increase reflects ALTO-207's blockbuster potential in TRD along with Alto's announced financing and "clear" regulatory path, the analyst tells investors in a research note.
Baird
Outperform
maintain
$10 -> $16
2025-10-21
Reason
Baird
Price Target
$10 -> $16
2025-10-21
maintain
Outperform
Reason
Baird raised the firm's price target on Alto Neuroscience to $16 from $10 and keeps an Outperform rating on the shares. The firm updated its model following the recent financing which shuld accelerate the timeline for the development of ALTO-207.
Baird
Baird
Outperform
maintain
$10 -> $16
2025-10-20
Reason
Baird
Baird
Price Target
$10 -> $16
2025-10-20
maintain
Outperform
Reason
Baird raised the firm's price target on Alto Neuroscience to $16 from $10 and keeps an Outperform rating on the shares after Alto announced a positive FDA update and $50M PIPE. Baird is encouraged by the additional liquidity and the streamlined plans to advance ALTO-207 to the pivotal stage in treatment-resistant depression, and tells investors in a research note that data showing 96%-100% of patients met pharmacokinetic positivity thresholds from ALTO-100 BPD and ALTO-101 CIAS Phase 2b trials indicate Alto is effectively mitigating patient compliance risk following the ALTO-100 major depressive disorder Phase 2b compliance issues
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alto Neuroscience Inc (ANRO.N) is -5.78, compared to its 5-year average forward P/E of -3.07. For a more detailed relative valuation and DCF analysis to assess Alto Neuroscience Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.07
Current PE
-5.78
Overvalued PE
-1.11
Undervalued PE
-5.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.79
Undervalued EV/EBITDA
-0.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 159.2% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ANRO News & Events

Events Timeline

(ET)
2025-10-20
07:15:41
Alto Neuroscience to Offer 3.832 Million Shares at $5.91 in Private Placement
select
2025-10-20
07:12:47
Alto Neuroscience aims to expedite the advancement of ALTO-207.
select
2025-10-03 (ET)
2025-10-03
07:38:09
Alto Neuroscience Receives Fast Track Designation for ALTO-101
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-04Newsfilter
Alto Neuroscience Grants 150,000 Stock Options at $12.80 to New Employee
  • Option Grant: On December 2, 2025, Alto Neuroscience granted a new employee an option to purchase 150,000 shares at an exercise price of $12.80, equal to the closing price on the grant date, aimed at attracting talent and enhancing employee loyalty.
  • Long-term Incentive Structure: The option has a 10-year term and vests over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments, ensuring continued employee contribution during their service.
  • Compliance Assurance: This grant complies with NYSE Listed Company Manual Rule 303A.08, ensuring the company's adherence to regulations while attracting and retaining key talent with transparency.
  • Strategic Implications: By implementing this incentive plan, Alto not only enhances its attractiveness but also demonstrates confidence in future growth, aiming to reshape the field of psychiatry through innovative drug development.
[object Object]
Preview
7.0
12-01Globenewswire
Johnson Fistel, PLLP Launches Investigation for Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)

  • Investigation of Shareholder Claims: Johnson Fistel, PLLP is investigating potential claims for shareholders of Alto Neuroscience, Atkore Inc., Dow Inc., and Fly-E Group, Inc. regarding alleged breaches of fiduciary duty by their officers and directors.

  • Allegations Against Alto Neuroscience: A federal securities class action claims that Alto Neuroscience misrepresented the effectiveness of its drug candidate ALTO-100, leading to investor losses when the truth about its efficacy was revealed.

  • Concerns with Atkore Inc.: A pending class action alleges that Atkore participated in an anticompetitive price-fixing scheme that inflated prices for PVC pipe products, resulting in financial performance issues once scrutiny increased.

  • Issues with Dow Inc. and Fly-E Group: Dow is accused of misleading investors about its dividend sustainability amid macroeconomic pressures, while Fly-E faces allegations of downplaying safety issues related to its lithium-battery technology, both leading to significant stock price declines.

[object Object]
Preview
2.0
11-18Benzinga
Major Stocks on the Rise Monday: Jazz Pharmaceuticals, Sigma Lithium, Zymeworks, and More

  • U.S. Stock Market Overview: U.S. stocks declined on Monday, with the Dow Jones index dropping over 100 points, while several individual stocks saw significant gains.

  • Jazz Pharmaceuticals Surge: Jazz Pharmaceuticals' shares rose 18% to $166.56 following positive results from a Phase 3 trial for its cancer treatment Ziihera.

  • Notable Stock Performances: PACS Group's shares jumped 49.5%, Sigma Lithium gained 30.5%, and Zymeworks rose 29.5%, among other notable stock increases.

  • Analyst Upgrades and Positive Data: Companies like Vita Coco and Alto Neuroscience received analyst upgrades, contributing to their stock price increases, while several firms reported strong clinical trial results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alto Neuroscience Inc (ANRO) stock price today?

The current price of ANRO is 13.38 USD — it has decreased -0.07 % in the last trading day.

arrow icon

What is Alto Neuroscience Inc (ANRO)'s business?

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

arrow icon

What is the price predicton of ANRO Stock?

Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 30.71 USD with a low forecast of 15.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alto Neuroscience Inc (ANRO)'s revenue for the last quarter?

Alto Neuroscience Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Alto Neuroscience Inc (ANRO)'s earnings per share (EPS) for the last quarter?

Alto Neuroscience Inc. EPS for the last quarter amounts to -0.52 USD, decreased -16.13 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alto Neuroscience Inc (ANRO)'s fundamentals?

The market is revising No Change the revenue expectations for ANRO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 264.58%.
arrow icon

How many employees does Alto Neuroscience Inc (ANRO). have?

Alto Neuroscience Inc (ANRO) has 76 emplpoyees as of December 05 2025.

arrow icon

What is Alto Neuroscience Inc (ANRO) market cap?

Today ANRO has the market capitalization of 415.67M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free